Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/22706
Başlık: | Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy |
Yazarlar: | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. 0000-0002-3425-0740 Özkan, Hasan Atilla Hakyemez, Bahattin Özkalemkaş, Fahir Ali, Rıdvan Özkocaman, Vildan Özçelik, Tülay Taşkapılıoğlu, Özlem Altundal, Yıldız Tunalı, Ayfer X-3647-2018 AAI-2318-2021 AAG-8495-2021 AAH-1854-2021 9250698600 6602527239 6601912387 7201813027 6603145040 7005424333 23037226400 15080726300 6602797853 |
Anahtar kelimeler: | Neurosciences & neurology Radiology, nuclear medicine & medical imaging Tumor lysis syndrome Reversible posterior leukoencephalopathy syndrome MRI Chemotherapy Leukemia Lymphoma Vasospasm Patient Combination chemotherapy Encephalopathy syndrome |
Yayın Tarihi: | 2006 |
Yayıncı: | Springer |
Atıf: | Özkan, A. vd. (2006). ''Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy''. Neuroradiology, 48(12), 887-892. |
Özet: | Introduction Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities. Method We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome. Results The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome. Conclusion Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned. |
URI: | https://doi.org/10.1007/s00234-006-0142-8 https://link.springer.com/article/10.1007/s00234-006-0142-8 http://hdl.handle.net/11452/22706 |
ISSN: | 0028-3940 1432-1920 |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.